Nav: Home

Breast cancer patients who take heart drug with trastuzumab have less heart damage

December 05, 2018

Milan, Italy - 5 December 2018: Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage, according to a study presented today at EuroEcho-Imaging 2018.1

"Heart damage is a major side effect of the breast cancer drug trastuzumab and may force patients to stop treatment," said lead author Dr Maryam Moshkani Farahani, associate professor, Baqiyatallah University of Medical Sciences, Tehran, Iran. "Our study suggests that patients who take the beta-blocker carvedilol together with trastuzumab have less heart damage than those who take trastuzumab alone."

The study enrolled 71 patients with non-metastatic HER2-positive breast cancer. Patients were randomly allocated to receive trastuzumab with, or without, carvedilol.

Impaired function of the heart's left ventricle is the main type of heart damage caused by trastuzumab. Carvedilol is used to treat patients with impaired left ventricular function after a heart attack. It is also prescribed for heart failure and high blood pressure.

For the study, an imaging technique called two-dimensional speckle tracking echocardiography was used to assess the systolic and diastolic function of the left ventricle initially and at three months. Specifically, systolic function was measured using global longitudinal strain and strain rate, while diastolic function was assessed with strain rate.

According to all of the measurements, systolic and diastolic left ventricular function were better preserved at three months in patients who took carvedilol with trastuzumab compared to those who took trastuzumab alone.

The pumping function of the heart (left ventricular ejection fraction) did not differ between treatment groups at the start of the study or at three months. "The measures we used to assess left ventricular function - namely global longitudinal strain and strain rate - are more sensitive than left ventricular ejection fraction," explained Dr Moshkani Farahani.

Dr Moshkani Farahani noted that carvedilol can cause side effects, such as dizziness, drowsiness, fainting, mood changes, shortness of breath, and diarrhoea. Patients who feel unwell when taking the medication should consult their doctor.

She concluded: "The findings indicate that carvedilol may be an effective way to prevent the heart damage caused by trastuzumab treatment. We now advise our patients with non-metastatic HER2-positive breast cancer to take prophylactic carvedilol, but a larger study is needed before firm recommendations can be made."
-end-
Authors: ESC Press Office Tel: +33 (0)4 8987 2499 Email: press@escardio.org

Follow ESC latest news on Twitter @ESCardioNews

Notes to editor

SOURCES OF FUNDING: None.

DISCLOSURES: None.

References and notes

1The abstract 'Assessment of treatment with carvedilol in preventing early stage left ventricular dysfunction in breast cancer patients by 2D speckle tracking echocardiography' will be presented during Poster session 1: Tissue Doppler, Speckle Tracking and Strain Imaging on 5 December, 09:00 to 16:00 CET, in the Poster area.

About the European Association of Cardiovascular Imaging (EACVI)

The European Association of Cardiovascular Imaging (EACVI) - a branch of the ESC - is the world leading network of Cardiovascular Imaging (CVI) experts, gathering four imaging modalities under one entity (Echocardiography, Cardiovascular Magnetic Resonance, Nuclear Cardiology and Cardiac Computed Tomography). Its aim is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging. The EACVI welcomes over 11,000 professionals including cardiologists, sonographers, nurses, basic scientists and allied professionals.

About the European Society of Cardiology

The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

Information for journalists attending EuroEcho-Imaging 2018

EuroEcho-Imaging 2018 takes place 5 to 8 December at the MiCo Milano Congressi in Milan, Italy. Explore the scientific programme.
  • To register on-site please bring a valid press card or appropriate letter of assignment with proof of three recent published articles (cardiology or health-related, or referring to a previous ESC Event).


European Society of Cardiology

Related Trastuzumab Articles:

Adding a second HER2 blocker may lower chance of invasive breast cancer for some women
A phase III clinical trial of 4,805 women with HER2-positive breast cancer suggests adding a second HER2 targeted medicine, pertuzumab (Perjeta), to standard of care trastuzumab (Herceptin) after surgery may help, although the benefit is modest.
Researchers identify biomarkers of response to treatment in invasive breast cancer
Researchers report at the San Antonio Breast Cancer Symposium that they have identified biomarkers they believe can be used as part of a larger model to predict how patients with HER2-positive operative breast cancer will respond to the targeted treatment trastuzumab, commercially known as Herceptin, and chemotherapy.
Proposed biosimilar drug shows potential as breast cancer treatment
Among women with metastatic breast cancer, treatment with a drug that is biosimilar to the breast cancer drug trastuzumab resulted in an equivalent overall response rate at 24 weeks compared with trastuzumab, according to a study published online by JAMA.
MD Anderson study finds significant cost differences between breast cancer chemotherapy regimens
Costs associated with different breast cancer chemotherapy regimens can vary significantly, regardless of effectiveness, according to new research from The University of Texas MD Anderson Cancer Center.
Costs of similarly effective breast cancer treatments vary widely
A new study finds that the costs of breast cancer chemotherapy vary widely, even among treatment regimens with similar efficacy, and that patients bear a substantial out-of-pocket burden.
Researchers restore drug sensitivity in breast cancer tumors
A team of Case Western Reserve University School of Medicine cancer researchers has uncovered one way certain tumors resist vital medication.
MD Anderson study identifies significant cost differences between breast cancer chemotherapy regimens
Costs associated with different breast cancer chemotherapy regimens can vary significantly, regardless of effectiveness, according to new research from The University of Texas MD Anderson Cancer Center.
Breast cancer patients receiving Herceptin treatment should be monitored for heart damage at any age
Breast cancer patients undergoing treatment with trastuzumab-containing regimens should be monitored for heart damage regardless of age.
Neratinib plus paclitaxel vs. trastuzumab plus paclitaxel in breast cancer
While neratinib plus paclitaxel was not superior to trastuzumab plus paclitaxel as first-line treatment for ERBB2-positive metastatic breast cancer in terms of progression-free survival, the combination was associated with delayed onset and reduced frequency of central nervous system metastases, a finding that requires a larger study to confirm, according to an article published online by JAMA Oncology.
Older women, especially blacks, receive targeted breast cancer treatment at low rates
The advent of targeted drugs for a specific type of breast cancer -- HER2 positive -- has dramatically improved survival rates for women with the disease.

Related Trastuzumab Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Jumpstarting Creativity
Our greatest breakthroughs and triumphs have one thing in common: creativity. But how do you ignite it? And how do you rekindle it? This hour, TED speakers explore ideas on jumpstarting creativity. Guests include economist Tim Harford, producer Helen Marriage, artificial intelligence researcher Steve Engels, and behavioral scientist Marily Oppezzo.
Now Playing: Science for the People

#524 The Human Network
What does a network of humans look like and how does it work? How does information spread? How do decisions and opinions spread? What gets distorted as it moves through the network and why? This week we dig into the ins and outs of human networks with Matthew Jackson, Professor of Economics at Stanford University and author of the book "The Human Network: How Your Social Position Determines Your Power, Beliefs, and Behaviours".